Dermapharm Holding SE · ISIN: DE000A2GS5D8 · EQS - Company News

High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies

Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies   Impressive organic growth in existing branded pharmaceuticals business at German and international companies compensates for drop in revenue due to scheduled end of pandemic-related boom in vaccine production EBITDA (unadjusted) rises by 7.3% to EUR 147.0 million, unadjusted EBITDA margin improves by 1.9 percentage points to 25.4% Consolidated...

XETR:DMP Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Dermapharm Holding SE

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (15)
Short Selling (DE) (0)
Short Selling (UK) (0)
27 August 2024 07:30AM
High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies
DE000A2GS5D8
Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies   Impressive organic growth in existing branded pharmaceuticals business at German and international companies compensates for drop in revenue due to scheduled end of pandemic-related boom in vaccine...
Dermapharm Holding SE
About the publication
14 August 2024 07:30AM
Sustained organic growth in high-margin existing branded pharmaceutical business
DE000A2GS5D8
Dermapharm Holding SE: Sustained organic growth in high- margin existing branded pharmaceutical business   Strong organic growth of existing branded pharmaceutical business across virtually every market compensates for effects from scheduled end of pandemic phase in vaccine cooperation Consolidated revenue and (adjusted) EBITDA thus drop slightl...
Dermapharm Holding SE
About the publication
27 June 2024 06:15PM
Annual General Meeting resolves dividend distribution of EUR 0.88 per share
DE000A2GS5D8
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share   2024 outlook confirmed Board of Management and Supervisory Board actions ratified with large majority Shareholders resolve dividend payment of EUR 0.88 per share Distribution ratio: approximately 78% of consolidated net profit   Grünwald, 27 J...
Dermapharm Holding SE
About the publication
15 May 2024 07:30AM
Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy
DE000A2GS5D8
Strong organic growth in core marketsunderscores resilience of Dermapharm Holding SE's corporate strategy    Robust, double-digit organic growth in high-margin "branded pharmaceuticals" largely offsets projected decline in vaccine production. Revenue in "Other healthcare products" segment down year on year due to temporary consumer reticence, pa...
Dermapharm Holding SE
About the publication
28 March 2024 07:30AM
Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges
DE000A2GS5D8
Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges   » Consolidated revenue up year on year by 10.8% to EUR 1,135.4 million » Adjusted consolidated EBITDA declines 13.8% to EUR 310.2 million » Adjusted consolidated EBITDA margin at 27.3% » Earnings decline as boom from vaccine business fades » Dividend p...
Dermapharm Holding SE
About the publication
14 March 2024 07:30AM
Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
DE000A2GS5D8
Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business     » Consolidated revenue up 10.8% year on year to EUR 1,135.4 million » Adjusted consolidated EBITDA declines by 13.8% to EUR 310.2 million » Adjusted consolidated EBITDA margin: 27.3% » Bo...
Dermapharm Holding SE
About the publication
15 November 2023 07:30AM
Dermapharm Holding SE builds on success in Q3 2023
DE000A2GS5D8
Dermapharm Holding SE builds on success in Q3 2023     Consolidated revenue and EBITDA (adjusted) stay on course, climbing to EUR 866.6 million and EUR 243.8 million, respectively Expansion driven by strong organic growth in the diversified product portfolio and the acquisition of the Arkopharma Group Adjusted consolidated EBITDA margin at 28.1...
Dermapharm Holding SE
About the publication
29 August 2023 07:30AM
Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
DE000A2GS5D8
Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall     Consolidated revenue and EBITDA (adjusted) stay on course, climbing year on year to EUR 582.1 million and EUR 168.0 million, respectively Expansion driven by Arkopharma Group and strong organic growth in branded pharmaceuticals and other healthcare p...
Dermapharm Holding SE
About the publication
16 August 2023 07:30AM
First half of 2023 is a success despite the challenging market environment
DE000A2GS5D8
Dermapharm Holding SE: First half of 2023 is a success despite the challenging market environment     Consolidated revenue and EBITDA (adjusted) continue to grow as planned to EUR 582 million and EUR 168 million, respectively, compared to the corresponding period of the previous year Growth driven by Arkopharma Group and strong organic growth o...
Dermapharm Holding SE
About the publication
14 June 2023 05:00PM
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 1.05 per share
DE000A2GS5D8
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 1.05 per share     2023 outlook confirmed Board of Management and Supervisory Board actions ratified with large majority Shareholders resolve dividend payment of EUR 1.05 per share Distribution ratio: approximately 42% of consolidated net profit   Grünwald, 1...
Dermapharm Holding SE
About the publication
14 June 2023 05:00PM
Annual General Meeting resolves dividend distribution of EUR 1.05 per share
DE000A2GS5D8
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 1.05 per share     2023 outlook confirmed Board of Management and Supervisory Board actions ratified with large majority Shareholders resolve dividend payment of EUR 1.05 per share Distribution ratio: approximately 42% of consolidated net profit   Grünwald, 1...
Dermapharm Holding SE
About the publication
13 June 2023 03:15PM
Dermapharm Holding SE invests in family-owned Austrian pharmaceutical company Montavit
DE000A2GS5D8
Dermapharm Holding SE invests in family-owned Austrian pharmaceutical company Montavit     Grünwald, 13 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, contractually acquired a significant interest in Pharmazeutische Fabrik Montavit Gesellschaft m.b.H. ("Montavit"), Absam, Tyrol, Aust...
Dermapharm Holding SE
About the publication
13 June 2023 03:15PM
Dermapharm Holding SE invests in family-owned Austrian pharmaceutical company Montavit
DE000A2GS5D8
Dermapharm Holding SE invests in family-owned Austrian pharmaceutical company Montavit     Grünwald, 13 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, contractually acquired a significant interest in Pharmazeutische Fabrik Montavit Gesellschaft m.b.H. ("Montavit"), Absam, Tyrol, Aust...
Dermapharm Holding SE
About the publication
15 May 2023 07:30AM
Dermapharm Holding SE: outstanding start to financial year 2023
DE000A2GS5D8
Dermapharm Holding SE: outstanding start to financial year 2023     Consolidated revenue up 37.8% to EUR 319.1 million Adjusted consolidated EBITDA rises 40.9% to EUR 105.8 million Strong organic growth in the existing portfolio Arkopharma Group acquired in January 2023 contributes to revenue and earnings for the first time Board of Manageme...
Dermapharm Holding SE
About the publication
15 May 2023 07:30AM
outstanding start to financial year 2023
DE000A2GS5D8
Dermapharm Holding SE: outstanding start to financial year 2023     Consolidated revenue up 37.8% to EUR 319.1 million Adjusted consolidated EBITDA rises 40.9% to EUR 105.8 million Strong organic growth in the existing portfolio Arkopharma Group acquired in January 2023 contributes to revenue and earnings for the first time Board of Manageme...
Dermapharm Holding SE
About the publication
28 March 2023 07:29AM
Dermapharm Holding SE surpasses one billion in revenue for first time in 2022 and maintains growth trajectory
DE000A2GS5D8
Dermapharm Holding SE surpasses one billion in revenue for first time in 2022 and maintains growth trajectory » Consolidated revenue rises 8.7% to EUR 1,024.8 million » Adjusted consolidated EBITDA grows by 2.5% to EUR 359.8 million » Consolidated revenue expected to increase to between EUR 1,080 and 1,110 billion in 2023 » Adjusted consolidate...
Dermapharm Holding SE
About the publication
28 March 2023 07:29AM
Dermapharm Holding SE: Dermapharm Holding SE surpasses one billion in revenue for first time in 2022 and maintains growth trajectory
DE000A2GS5D8
Dermapharm Holding SE surpasses one billion in revenue for first time in 2022 and maintains growth trajectory » Consolidated revenue rises 8.7% to EUR 1,024.8 million » Adjusted consolidated EBITDA grows by 2.5% to EUR 359.8 million » Consolidated revenue expected to increase to between EUR 1,080 and 1,110 billion in 2023 » Adjusted consolidate...
Dermapharm Holding SE
About the publication
22 March 2023 11:00AM
Dermapharm Holding SE: 2022 dividend
DE000A2GS5D8
Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse(Market Abuse Regulation, "MAR") Dermapharm Holding SE: 2022 dividend Grünwald, 22 March 2023 – At its meeting today, the Board of Management of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) resol...
Dermapharm Holding SE
About the publication
22 March 2023 11:00AM
2022 dividend
DE000A2GS5D8
Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse(Market Abuse Regulation, "MAR") Dermapharm Holding SE: 2022 dividend Grünwald, 22 March 2023 – At its meeting today, the Board of Management of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) resol...
Dermapharm Holding SE
About the publication
14 March 2023 07:30AM
Dermapharm Holding SE: Dermapharm Holding SE's revenue exceeds one billion for the first time
DE000A2GS5D8
Dermapharm Holding SE's revenue exceeds one billion for the first time » Consolidated revenue up 8.7 % year on year to EUR 1,025 million » Adjusted consolidated EBITDA increases by 2.5 % to EUR 360 million » Adjusted consolidated EBITDA margin: 35.1% » Broad product portfolio drives success » Revenue expected to continue growing in 2023 Grünw...
Dermapharm Holding SE
About the publication
14 March 2023 07:30AM
Dermapharm Holding SE's revenue exceeds one billion for the first time
DE000A2GS5D8
Dermapharm Holding SE's revenue exceeds one billion for the first time » Consolidated revenue up 8.7 % year on year to EUR 1,025 million » Adjusted consolidated EBITDA increases by 2.5 % to EUR 360 million » Adjusted consolidated EBITDA margin: 35.1% » Broad product portfolio drives success » Revenue expected to continue growing in 2023 Grünw...
Dermapharm Holding SE
About the publication
05 January 2023 03:17PM
Dermapharm Holding SE intensifies its internationalisation efforts by acquiring Arkopharma
DE000A2GS5D8
Dermapharm Holding SE intensifies its internationalisation efforts by acquiring Arkopharma   Internationalisation expanded in Western and Southern Europe Strengthening expertise in the development of innovative food supplements Synergies in marketing OTC health products Revenue growth of more than EUR 200 million   Grünwald, 5 January 2023 – ...
Dermapharm Holding SE
About the publication
16 November 2022 07:30AM
Dermapharm Holding SE successfully maintains growth trend as planned
DE000A2GS5D8
Dermapharm Holding SE successfully maintains growth trend as planned   Consolidated revenue up 9.6% to EUR 734.3 million Adjusted consolidated EBITDA rises 5.1% to EUR 239.4 million Adjusted consolidated EBITDA margin: 32.6% "Parallel import business" segment rebounds Board of Management confirms outlook for 2022 overall   Grünwald, 16 Novem...
Dermapharm Holding SE
About the publication
16 November 2022 07:30AM
Dermapharm Holding SE successfully maintains growth trend as planned
DE000A2GS5D8
Dermapharm Holding SE successfully maintains growth trend as planned   Consolidated revenue up 9.6% to EUR 734.3 million Adjusted consolidated EBITDA rises 5.1% to EUR 239.4 million Adjusted consolidated EBITDA margin: 32.6% "Parallel import business" segment rebounds Board of Management confirms outlook for 2022 overall   Grünwald, 16 Novem...
Dermapharm Holding SE
About the publication
07 September 2022 07:30AM
Dermapharm Holding SE publishes H1 2022 financial report, confirms outlook for 2022 overall
DE000A2GS5D8
Dermapharm Holding SE publishes H1 2022 financial report, confirms outlook for 2022 overall   » Consolidated revenue up year on year by 10.1% to EUR 471.1 million » Adjusted consolidated EBITDA grew by 8.5% to EUR 148.7 million » Adjusted consolidated EBITDA margin: 31.6% » Broadly diversified product portfolio is a key success factor » Outlo...
Dermapharm Holding SE
About the publication
07 September 2022 07:30AM
Dermapharm Holding SE publishes H1 2022 financial report, confirms outlook for 2022 overall
DE000A2GS5D8
Dermapharm Holding SE publishes H1 2022 financial report, confirms outlook for 2022 overall   » Consolidated revenue up year on year by 10.1% to EUR 471.1 million » Adjusted consolidated EBITDA grew by 8.5% to EUR 148.7 million » Adjusted consolidated EBITDA margin: 31.6% » Broadly diversified product portfolio is a key success factor » Outlo...
Dermapharm Holding SE
About the publication
23 August 2022 07:30AM
Dermapharm Holding SE: Successful first half of 2022 in challenging market environment
DE000A2GS5D8
Dermapharm Holding SE: Successful first half of 2022 in challenging market environment   Consolidated revenue increased by 10% to EUR 471 million Adjusted Group EBITDA increases by 9% to EUR 149 million Broadly diversified product portfolio as an important guarantee for success Implementation of the C³ Group according to plan Management Board...
Dermapharm Holding SE
About the publication
23 August 2022 07:30AM
Successful first half of 2022 in challenging market environment
DE000A2GS5D8
Dermapharm Holding SE: Successful first half of 2022 in challenging market environment   Consolidated revenue increased by 10% to EUR 471 million Adjusted Group EBITDA increases by 9% to EUR 149 million Broadly diversified product portfolio as an important guarantee for success Implementation of the C³ Group according to plan Management Board...
Dermapharm Holding SE
About the publication
30 July 2022 08:26PM
Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements
DE000A2GS5D8
Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements Grünwald, July 30, 2022 – Today, Dermapharm Holding SE ("Dermapharm"), a fast-growing manufacturer of branded pharmaceuticals, acting via its wholly owned subsidiary Dermapharm AG, submitted a binding offer to acquire 100% of the shares in Aph...
Dermapharm Holding SE
About the publication
30 July 2022 08:26PM
Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements
DE000A2GS5D8
Dermapharm commits to acquire the French market leader for herbal medicinal products and food supplements Grünwald, July 30, 2022 – Today, Dermapharm Holding SE ("Dermapharm"), a fast-growing manufacturer of branded pharmaceuticals, acting via its wholly owned subsidiary Dermapharm AG, submitted a binding offer to acquire 100% of the shares in Aph...
Dermapharm Holding SE
About the publication
30 July 2022 08:22PM
Dermapharm Holding SE: binding offer to acquire Arkopharma Group
DE000A2GS5D8
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU) No. 596/2014 on market abuse, as amended (Market Abuse Regulation – MAR) Dermapharm Holding SE: binding offer to acquire Arkopharma Group Grünwald, July 30, 2022 – Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D...
Dermapharm Holding SE
About the publication
30 July 2022 08:22PM
binding offer to acquire Arkopharma Group
DE000A2GS5D8
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU) No. 596/2014 on market abuse, as amended (Market Abuse Regulation – MAR) Dermapharm Holding SE: binding offer to acquire Arkopharma Group Grünwald, July 30, 2022 – Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D...
Dermapharm Holding SE
About the publication
18 May 2022 07:30AM
Dermapharm Holding SE: excellent start into financial year 2022
DE000A2GS5D8
Dermapharm Holding SE: excellent start into financial year 2022 - Consolidated revenue up 9.1% to EUR 231.6 million - Adjusted consolidated EBITDA rises 17.9% to EUR 75.1 million - Newly-acquired C³ Group contributes to revenue and earnings for the first time - Sustained high demand for products to strengthen the immune system - Board of Manag...
Dermapharm Holding SE
About the publication
12 April 2022 07:30AM
Dermapharm Holding SE records best ever year in 2021 - continuous growth in financial year 2022
DE000A2GS5D8
Dermapharm Holding SE records best ever year in 2021 - continuous growth in financial year 2022 » Consolidated revenue rises 18.8% to EUR 942.9 million » Adjusted consolidated EBITDA grows by 74.9% to EUR 351.1 million » Consolidated revenue expected to increase by 10-13% in 2022 » Consolidated EBITDA forecasted to rise by 3-7% in 2022 » Divi...
Dermapharm Holding SE
About the publication
29 March 2022 07:30AM
Dermapharm Holding SE: Continuous growth of Group revenues and adjusted Group EBITDA in 2022
DE000A2GS5D8
Dermapharm Holding SE: Continuous growth of Group revenues and adjusted Group EBITDA in 2022 » Group revenue to grow by 10% to 13% year-on-year » Increase in adjusted Group EBITDA of 3% to7 % compared to previous year » Additional revenue and earnings contribution from integration of cannabis business » Expansion of vaccine cooperation with Bio...
Dermapharm Holding SE
About the publication
22 March 2022 07:30AM
Dermapharm Holding SE: Most successful business year in the company's history - Adjusted Group EBITDA at the upper end of the outlook
DE000A2GS5D8
Dermapharm Holding SE: Most successful business year in the company's history - Adjusted Group EBITDA at the upper end of the outlook » Group turnover increased by around 19% versus previous year to EUR 943 million » Adjusted Group EBITDA increased by around 75% to EUR 351 million » Adjusted Group EBITDA margin of 37.2% » Strong demand for immu...
Dermapharm Holding SE
About the publication
31 January 2022 10:02AM
Dermapharm successfully acquires C³ Group
DE000A2GS5D8
Dermapharm successfully acquires C³ Group Grünwald, 31 January 2022 - Dermapharm Holding SE ("Dermapharm"), a fast-growing manufacturer of branded pharmaceuticals, has successfully completed the acquisition of the C³ Cannabinoid Compound Company GmbH ("C³ Group"). Today, Monday 31 January 2022, the closing of the acquisition of C³ Cannabinoid C...
Dermapharm Holding SE
About the publication
16 December 2021 12:10PM
Dermapharm Holding SE raises EBITDA forecast for the full year 2021
DE000A2GS5D8
Dermapharm Holding SE raises EBITDA forecast for the full year 2021 Grünwald, December 16, 2021 - Dermapharm Holding SE ("Dermapharm"), a high-growth manufacturer of branded pharmaceuticals, is raising its guidance for adjusted Group EBITDA. The Management Board now expects an improvement of 70% to 75% compared to the previous year and confirms t...
Dermapharm Holding SE
About the publication
16 December 2021 12:08PM
Dermapharm Holding SE raises EBITDA forecast for the full year 2021
DE000A2GS5D8
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU) No. 596/2014 on market abuse, as amended (Market Abuse Regulation - MAR) Dermapharm Holding SE raises EBITDA forecast for the full year 2021 Grünwald, December 16, 2021 - The Management Board of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) analysed the bu...
Dermapharm Holding SE
About the publication
15 December 2021 01:48PM
Dermapharm Holding SE acquires C³-Group and expands its activities in the cannabis market
DE000A2GS5D8
Dermapharm Holding SE acquires C³-Group and expands its activities in the cannabis market Grünwald, December 15, 2021 - Dermapharm Holding SE ("Dermapharm"), a fast-growing manufacturer of branded pharmaceuticals, is acquiring C³ Cannabinoid Compound Company GmbH ("C³ Group"), which specialises in the development, production and marketing of natur...
Dermapharm Holding SE
About the publication
15 December 2021 01:45PM
Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH
DE000A2GS5D8
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU) No. 596/2014 on market abuse, as amended (Market Abuse Regulation - MAR) Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH Grünwald, December 15, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), through Dermapharm AG, today en...
Dermapharm Holding SE
About the publication
16 November 2021 07:30AM
Dermapharm Holding SE: strong EBITDA growth in Q3 2021
DE000A2GS5D8
Dermapharm Holding SE: strong EBITDA growth in Q3 2021 - Consolidated revenue up 16.1% to EUR 670.2 million - Adjusted consolidated EBITDA rises 63.9% to EUR 227.8 million - Sustained high demand for products to strengthen the immune system - Investments in fill & finish production facilities for Comirnaty(R) - "Herbal extracts" segment s...
Dermapharm Holding SE
About the publication
07 September 2021 07:30AM
Dermapharm Holding SE publishes H1 2021 report, confirms outlook for 2021 overall
DE000A2GS5D8
Dermapharm Holding SE publishes H1 2021 report, confirms outlook for 2021 overall » Consolidated revenue up year on year by 13% to EUR 428 million » Adjusted consolidated EBITDA up approximately 50% year on year at EUR 137 million » Adjusted consolidated EBITDA margin improves to 32.0% » Sustained high demand for products to strengthen the immune...
Dermapharm Holding SE
About the publication
24 August 2021 07:30AM
Dermapharm Holding SE: Adjusted EBITDA up almost 50% in H1 2021
DE000A2GS5D8
Dermapharm Holding SE: Adjusted EBITDA up almost 50% in H1 2021   - Consolidated revenue up 13% to EUR 428 million - Adjusted consolidated EBITDA rises 49% to EUR 137 million - Adjusted consolidated EBITDA margin improves to 32.0% - Sustained high demand for products to strengthen the immune system - Board of Management confirms outlook for 20...
Dermapharm Holding SE
About the publication
07 July 2021 04:45PM
Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH
DE000A2GS5D8
Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH Grünwald, 7 July 2021 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, is expanding its group of companies via Dermapharm AG to include an investment in the area of immunotherapies against COVID-19. To this end, Dermapharm ...
Dermapharm Holding SE
About the publication
07 July 2021 04:39PM
Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH
DE000A2GS5D8
Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation, "MAR") Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH Grünwald, 7 July 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) today, via Derma...
Dermapharm Holding SE
About the publication
23 June 2021 02:30PM
Dermapharm Holding SE: Annual General Meeting approves dividend distribution of EUR 0.88 per share
DE000A2GS5D8
Dermapharm Holding SE: Annual General Meeting approves dividend distribution of EUR 0.88 per share   - Board of Management and Supervisory Board actions ratified with large majority - Shareholders approve EUR 0.88 dividend - Distribution ratio: approximately 55% of consolidated net profit - 2021 marked by extraordinary growth - 2021 outlook c...
Dermapharm Holding SE
About the publication
18 May 2021 07:30AM
Dermapharm Holding SE: accelerated EBITDA growth in Q1 2021
DE000A2GS5D8
Dermapharm Holding SE: accelerated EBITDA growth in Q1 2021 - Consolidated revenue up 10.2% to EUR 212.2 million - Adjusted consolidated EBITDA rises 28.9% to EUR 63.7 million - Sustained high demand for products to strengthen the immune system - Vaccine production at Allergopharma GmbH & Co. KG off to a successful start - Board of Manage...
Dermapharm Holding SE
About the publication
More Dermapharm Holding SE related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 15 5th November 2024 Dreibholz, Christof DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN